Having established improved cancer detection, the interval cancer rate will reveal whether AI catches certain early cancers missed by standard screening.

Researchers found the therapy downregulated VEGF expression and improved retinal thickness in neovascular age-related macular degeneration patients.

NEW YORK – Erasca said on Tuesday it is prioritizing development of its recently acquired preclinical RAS programs, pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, and will be ...

The firm will test CAP-002 in a Phase I/IIa trial involving patients with syntaxin-binding protein 1 developmental and epileptic encephalopathy.

The funds will support multiple new and ongoing clinical trials of Tilt's oncolytic adenoviral therapy TILT-123.

The firm will test the drug with immune checkpoint inhibitors in NSCLC patients with low PD-L1 expression and KEAP1 and/or STK11 mutations.

India already has a homegrown CAR T-cell therapy, and other regions are exploring their own strategies, including developing them at the point of care.

From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder ...

Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

The FDA will issue a decision on the BLA for RGX-121 by November, which if positive, could make it the first gene therapy for Hunter syndrome.

After seeing promising results in preclinical studies, the firm hopes to begin Phase I trials shortly after getting IND clearance.

In his first term, pharmaceutical companies took the "most favored nation" policy to court over the White House's effort to slash costs for patients.